Table of Contents
It is a skin cream that helps women to get rid of unwanted facial hair. Eflornithine can prevent the growth of undesirable hair on the face in women, most commonly around the lips or under the chin. Eflornithine reduces hair growth by inhibiting a natural chemical found in the hair follicle (the area where each hair develops). 
Benefits Of Eflornithine Cream:
Women’s facial hirsutism is a cosmetic problem that can cause major worry and low self-esteem. For the treatment of facial hirsutism, eflornithine cream is advised.
The effectiveness of eflornithine cream in reducing unwanted facial hair in female patients was assessed in two double-blind, randomized studies involving 594 female patients who received treatment twice daily for up to 24 weeks. Women in the trial typically had their facial hair removed twice a week or more. The trials excluded women with facial problems such as severe inflammatory acne, pregnant women, and nursing mothers. 
After 48 hours, doctors examined all treated regions for improvement or deterioration from the baseline condition. In each of these investigations, there was a statistically significant boost for eflornithine Cream, for “marked enhancement” or greater response. Consistently noticeable improvement was noted 8 weeks after treatment began and persisted for the full 24 weeks of the program. Within 8 weeks of stopping the treatment, hair growth started to resemble pretreatment levels. After twenty-four weeks of treatment with eflornithine hydrochloride Cream, 13.9% of patients demonstrated substantial improvement or more. 
Using a Franz diffusion cell, an in vitro permeation investigation of eflornithine was carried out. Monitoring the regrowth of hair in the lower dorsal skin of mice after the eflornithine cream was given to a region primed with microneedles allowed researchers to conduct an in vivo efficacy analysis using a mouse model. Additionally, a histological examination of the skin and hair follicles in the treated area was performed. 
An in vitro permeation investigation demonstrated that applying the eflornithine cream to a mouse skin area that had already received micro needling significantly improved the drug’s ability to prevent hair growth. This was most likely because the micropores created by the microneedles allowed eflornithine to permeate the skin. Data from immunohistochemistry showed that when the eflornithine cream was administered to a skin area that had already received micro-needling treatment, cell proliferation in the skin and hair follicles was dramatically suppressed.
Ornithine decarboxylase is hypothesized to delay hair growth by blocking this enzyme in hair follicles. Eflornithine is a selective, irreversible inhibitor of this enzyme. When the 15% cream was applied twice daily to a 50 cm2 area of shaved skin beneath the chin, the amount of eflornithine that was absorbed through the skin by women with undesired facial hair was less than 1%. After 2 to 8 weeks of treatment, eflornithine 15% cream outperformed the placebo in clinical investigations in women with excessive, undesired facial hair in terms of slowing hair growth, as shown by both objective and subjective measures. 
A minimum of some improvement in facial hirsutism was seen in 58% of eflornithine receivers and 34% of placebo recipients after 24 weeks of treatment. Additionally, 32 patients as opposed to 8% were considered to have received a successful treatment (at least a considerable improvement). Within eight weeks of finishing the medication, hair growth rates were back to pretreatment levels. Eflornithine reduced the mean degree of overall discomfort and bother by 33 against 15% in those who received a placebo, according to a self-assessment questionnaire used to evaluate the impact of study treatment on six elements of patient well-being. [5[
Is It Safe To Use During Pregnancy Pregnancy?
The FDA divides drugs into categories based on their suitability for usage during pregnancy. The potential dangers of taking medicine while pregnant are divided into five categories: A, B, C, D, and X. Vaniqa is classified as a C. Pregnant ladies have not been the subject of any reliable studies. Only if the potential advantages outweigh the potential risks to the developing fetus can Vaniqa be used during pregnancy. 
Categories For Pregnancies:
A: Generally acceptable. No fetal risk has been identified in controlled investigations of pregnant women.
B: Possibly agreeable. Animal studies either showed minimal dangers and human studies were done and showed no risk, or animal studies showed no risk but human studies were not available.
C: If the advantages outweigh the hazards, proceed with caution. Risk is demonstrated by animal studies, but human studies are either not accessible or have not been conducted.
D: When no safer medication is available, use in LIFE-THREATENING situations. Positive proof of fetal risk in humans.
X: Avoid using if pregnant. The risks outweigh any potential advantages. There are safer choices.
How To Use Eflornithine Cream?
The patient information leaflet for this medication is included. Read it thoroughly. You can ask any questions you may have regarding this medication to your physician, nurse, or chemist. Only apply a thin layer of this medication and thoroughly rub it into the chin and face areas that are affected. Typically, it is applied twice daily, at least eight hours apart, or as your doctor instructs. Applying after hair removal (such as plucking or shaving) must wait at least five minutes. Before cleaning the treated area, wait at least 4 hours.
Immediately after using this product, wash your hands. This procedure should only be carried out on the skin. Do not get the product in your mouth, nose, or eyes. Rinse quickly with fresh water if the drug gets in these locations. Contact your doctor and thoroughly rinse your eyes if this medication accidentally goes into them. Before applying cosmetics, moisturizers, or sunscreen to the affected regions, wait until the medication has completely dried.
In therapeutic use, eflornithine cream is not anticipated to result in contact sensitization, phototoxic, or photosensitization reactions, according to the findings of topical dermal investigations for contact sensitization, photo contact sensitization, and photo contact irritation. According to the results of the topical dermal trial for contact irritation, this cream may trigger allergic responses when used clinically in susceptible people or under circumstances that need excessive use.
Reduce the frequency of treatments if skin irritation occurs. Contact your doctor and stop taking the medication if irritation persists. After six months of treatment, cease taking the medication and call your doctor if no improvement has been noticed. Keep out of children’s reach. Store between 59 and 86 degrees Fahrenheit (15 to 30 degrees Celsius) at room temperature. Avoid freezing. After the expiration date, you should dispose of any unused medication. If your illness worsens while you’re taking the medication, stop taking it and call your doctor.
- Eflornithine skin cream. Retrieved from www. clevelandclinic.org:
- VANIQA – eflornithine hydrochloride cream Physicians Total Care, Inc. Retrieved from nih.gov:
- eflornithine cream (Rx). Retrieved from www.medscape.org:
- A method to improve the efficacy of topical eflornithine hydrochloride cream. Retrieved from nih.gov:
- Topical eflornithine. Retrieved from nih.gov:
- Eflornithine Cream – Uses, Side Effects, and More. Retrieved from www.webmed.org:
- Eflornithine (Topical Route). Retrieved from www.mayoclinic.org
Skin Care Professional
“Marcella Jiovanni actively promotes the importance of maintaining healthy skin, she envisions the future of dermatology as moving away from pure medical, pharmacological dermatology and flowing more toward a holistic approach to wellness and skincare.”